Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy

Amaia Lujambio1, Pablo Sarobe2

  • 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA.

Journal of Hepatology
|June 17, 2022
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos